The effect of ciprofibrate on gastric secretion in the rat.
The potential of ciprofibrate to inhibit gastric secretion has been investigated in the rat. A significant gastric antisecretory effect was observed following a single oral administration of 300 and 500 mg kg-1 and following a single intraduodenal dose of 100, 300 and 500 mg kg-1. The toxicological significance of this finding is discussed in the light of a spate of recent publications linking changes in gastric morphology with hypergastrinaemia produced as a secondary effect of inhibition of acid secretion.
Eason
C T
CT
Toxicology Department, Sterling-Winthrop Research Centre, Alnwick, Northumberland, UK.
Pattison
A
A
Howells
D D
DD
Bonner
F W
FW
D000818:Animals; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D058607:Fibric Acids; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008297:Male; D051379:Mice; D051381:Rats; D011916:Rats, Inbred F344; D012016:Reference Values
D058607:Fibric Acids; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; C019304:ciprofibrate; D002994:Clofibrate